Roxadustat
- Generic Name
- Roxadustat
- Brand Names
- Evrenzo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16N2O5
- CAS Number
- 808118-40-3
- Unique Ingredient Identifier
- X3O30D9YMX
- Background
Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. Roxadustat was first approved by...
- Indication
Roxadustat is indicated for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
- Associated Conditions
- Anemia
- Associated Therapies
- -
Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 72
- Registration Number
- NCT06115421
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT06006949
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05970172
- Locations
- 🇧🇪
Site BE32002, Brussels, Belgium
🇹🇷Site TR90010, Ankara, Turkey
🇧🇪Site BE32001, Edegem, Belgium
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Region Stockholm
- Target Recruit Count
- 30
- Registration Number
- NCT05810311
- Locations
- 🇸🇪
Centre for diabetes, Stockholm, Sweden
Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- China-Japan Friendship Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05691257
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 159
- Registration Number
- NCT05301517
- Locations
- 🇨🇳
Shandong First Medical University Cancer Hospital, Jinan, China
🇨🇳The Second Hospital of Lanzhou University, Lanzhou, China
🇨🇳Neijiang Second People's Hospital, Neijiang, China
Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 318
- Registration Number
- NCT05010460
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Mao Jianhua
- Target Recruit Count
- 30
- Registration Number
- NCT04925011
- Locations
- 🇨🇳
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04925661
- Locations
- 🇨🇳
The sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
🇨🇳Zhejiang Provincal People's Hospital, Hangzhou, China
🇨🇳The People's Hospital of Guangxi Zhuang Autonmous Region, Nanning, China
Study of Roxadustat in the Treatment of Acute Myocardial Infarction
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 158
- Registration Number
- NCT04803864
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.